COMP <GO>
ZVRA vs NVCT // ALTMAN Z-SCORE & DEBT/EQUITY
Zevra Therapeutics Inc. (NASDAQ) VS. Nuvectis Pharma Inc. (NASDAQ) • 15-METRIC TALLY: ZVRA 5
— NVCT 0
■ METRIC PARITY
LAST: $10.36 (+0.49%) • MKT CAP: $615.2M
balance-sheet
—
LAST: $18.57 (+1.14%) • MKT CAP: $605.6M
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZVRA VS. NVCT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZVRA | NVCT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.30% | -35.00% | +2.70 | ZVRA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.40% | -2.64% | +2.24 | ZVRA | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | ZVRA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 41.3 | +4.38 | ZVRA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.9x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $615.2M | $605.6M | $9.6M | ZVRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZVRA REV | NVCT REV | ZVRA GROSS % | NVCT GROSS % | ZVRA FCF | NVCT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$2.4M | -$16.0M |
| FY 2024 | $0 | $0 | — | — | -$69.7M | -$12.2M |
| FY 2023 | $0 | $0 | — | — | -$33.5M | -$16.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZVRA // BETA —
NVCT // BETA —